Celcuity Inc. (NASDAQ:CELC) Given Consensus Rating of “Buy” by Analysts

Celcuity Inc. (NASDAQ:CELC) has received a consensus rating of “Buy” from the seven brokerages that are presently covering the stock, Marketbeat reports. Six investment analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $30.17.

CELC has been the subject of several recent research reports. Needham & Company LLC boosted their target price on shares of Celcuity from $23.00 to $29.00 and gave the company a “buy” rating in a research report on Thursday, February 6th. HC Wainwright reissued a “buy” rating and set a $27.00 price objective on shares of Celcuity in a research report on Friday, November 15th.

Hedge Funds Weigh In On Celcuity

A number of hedge funds have recently modified their holdings of CELC. Soleus Capital Management L.P. raised its position in shares of Celcuity by 106.0% during the 4th quarter. Soleus Capital Management L.P. now owns 2,565,087 shares of the company’s stock valued at $33,577,000 after purchasing an additional 1,319,700 shares during the period. Shay Capital LLC purchased a new stake in Celcuity in the 4th quarter worth $187,000. Nuveen Asset Management LLC raised its holdings in Celcuity by 10.8% during the fourth quarter. Nuveen Asset Management LLC now owns 69,587 shares of the company’s stock valued at $911,000 after acquiring an additional 6,785 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Celcuity by 16.2% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 19,725 shares of the company’s stock valued at $258,000 after acquiring an additional 2,756 shares in the last quarter. Finally, J. Goldman & Co LP bought a new position in shares of Celcuity in the fourth quarter worth about $567,000. 63.33% of the stock is currently owned by institutional investors.

Celcuity Trading Up 11.7 %

Celcuity stock opened at $9.94 on Wednesday. Celcuity has a 52-week low of $8.53 and a 52-week high of $22.19. The company has a market cap of $369.07 million, a P/E ratio of -3.81 and a beta of 0.73. The company has a quick ratio of 10.36, a current ratio of 10.35 and a debt-to-equity ratio of 0.65. The business has a 50-day simple moving average of $11.99 and a two-hundred day simple moving average of $13.74.

Celcuity Company Profile

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.